Cargando…

Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs

It is common for patients to have limited access to oral antineoplastics or to discontinue treatment because of cost. Such oral treatments are also discontinued because of toxicity, disease progression, or death, resulting in unused portions of these medications. Policies for the subsequent use or d...

Descripción completa

Detalles Bibliográficos
Autores principales: Layton, Jodi L., Lewis, Brian, Ryan, Charles, Beer, Tomasz M., Sartor, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519754/
https://www.ncbi.nlm.nih.gov/pubmed/30568023
http://dx.doi.org/10.1634/theoncologist.2018-0565
_version_ 1783418658903556096
author Layton, Jodi L.
Lewis, Brian
Ryan, Charles
Beer, Tomasz M.
Sartor, Oliver
author_facet Layton, Jodi L.
Lewis, Brian
Ryan, Charles
Beer, Tomasz M.
Sartor, Oliver
author_sort Layton, Jodi L.
collection PubMed
description It is common for patients to have limited access to oral antineoplastics or to discontinue treatment because of cost. Such oral treatments are also discontinued because of toxicity, disease progression, or death, resulting in unused portions of these medications. Policies for the subsequent use or destruction of unused drugs exist, but none completely address the need for methods of recycling back to the patients in need. This article addresses this wastefulness and ways to minimize it so that more patients benefit.
format Online
Article
Text
id pubmed-6519754
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-65197542019-06-20 Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs Layton, Jodi L. Lewis, Brian Ryan, Charles Beer, Tomasz M. Sartor, Oliver Oncologist Commentaries It is common for patients to have limited access to oral antineoplastics or to discontinue treatment because of cost. Such oral treatments are also discontinued because of toxicity, disease progression, or death, resulting in unused portions of these medications. Policies for the subsequent use or destruction of unused drugs exist, but none completely address the need for methods of recycling back to the patients in need. This article addresses this wastefulness and ways to minimize it so that more patients benefit. John Wiley & Sons, Inc. 2018-12-19 2019-03 /pmc/articles/PMC6519754/ /pubmed/30568023 http://dx.doi.org/10.1634/theoncologist.2018-0565 Text en © AlphaMed Press 2018
spellingShingle Commentaries
Layton, Jodi L.
Lewis, Brian
Ryan, Charles
Beer, Tomasz M.
Sartor, Oliver
Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs
title Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs
title_full Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs
title_fullStr Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs
title_full_unstemmed Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs
title_short Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs
title_sort recycling discarded drugs: improving access to oral antineoplastic drugs
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519754/
https://www.ncbi.nlm.nih.gov/pubmed/30568023
http://dx.doi.org/10.1634/theoncologist.2018-0565
work_keys_str_mv AT laytonjodil recyclingdiscardeddrugsimprovingaccesstooralantineoplasticdrugs
AT lewisbrian recyclingdiscardeddrugsimprovingaccesstooralantineoplasticdrugs
AT ryancharles recyclingdiscardeddrugsimprovingaccesstooralantineoplasticdrugs
AT beertomaszm recyclingdiscardeddrugsimprovingaccesstooralantineoplasticdrugs
AT sartoroliver recyclingdiscardeddrugsimprovingaccesstooralantineoplasticdrugs